Amgen: Wonderful Stock At Decent Price
Amgen is a biotech company with a strong track record of returning capital to shareholders and maintaining high profitability. The company has outperformed the S&P 500 and other pharmaceutical peer...
Amgen: Bet On Its Breakthrough Drug
Amgen Inc. is a biotech company known for its innovative therapies and focus on areas with significant unmet medical needs. The company showcases strong financial health, with a past quarter of inc...
Amgen (AMGN) Advances But Underperforms Market: Key Facts
Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.
Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.
Amgen raises dividend to $2.25 a share
Amgen Inc. AMGN, +0.68% said late Tuesday its board has authorized a dividend of $2.25 a share, up from $2.13 a share. That's the 12th straight year that Amgen has increased its dividend, the compa...
Here's Why Amgen (AMGN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
6 Health Care Dividend Stocks To By Hand Over Fist
This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
3 Dividend Stocks for December 2023
#Morningstar #Fidelity #DividendStocks The dividend prospects for three firms with economic moats. 00:00 Introduction 00:10 Amgen AMGN 00:56 Enbridge ENB 01:56 Fidelity National Information Servic...
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Amgen (AMGN) closed at $269.35, marking a -0.56% move from the previous day.
December Dogs Of The Dow: 3 Buyable, 5 Watchable
"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”...
Amgen (AMGN) Up 2.2% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Biotech Stock for Options Bears
Subscribers to Schaeffer's Weekend Trader options recommendation service received this AMGN commentary on Sunday night, along with a detailed options trade recommendation -- including complete entr...
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-pickin...
3.2%-Yielding Amgen's Realistic Path To >11% Annual Returns
Amgen completes acquisition of Horizon Therapeutics, boosting long-term growth potential. Addition of TEPEZZA, KRYSTEXXA, and UPLIZNA strengthens Amgen's inflammation portfolio and global reach. Am...
Related Companies